Noonan syndrome (NS) is a relatively common autosomal dominant disorder characterized by short stature, dysmorphic facial features, congenital heart disease, cryptorchidism, and mild learning disabilities \[[@b1-kjp-2019-00220],[@b2-kjp-2019-00220]\]. Short stature is a common clinical feature in more than 50% of NS patients \[[@b2-kjp-2019-00220]\]. Birth weight and length in NS are usually within normal ranges, followed by a progressive growth failure until puberty. Pubertal development is generally delayed and pubertal growth shows a low peak \[[@b3-kjp-2019-00220]\].

NS is a genetically heterogeneous disorder with germline mutations affecting the RAS--mitogen-activated protein kinase (RAS-MAPK) signal transduction pathway, leading to dysregulation \[[@b4-kjp-2019-00220]\]. NS has variable clinical features and genetic complexity caused by mutations in several genes including *PTPN11, SOS1, RAF1, KRAS, NRAS, SHOC2, CBL, BRAF, SOS2, RIT1, RRAS, RASA2, SPRY1, LZTR1, MAP3K8, MYST4*, and *A2ML1* \[[@b5-kjp-2019-00220]\]. However, genetic mutations have not been identified in 20%--30% of all patients with NS.

The majority of NS patients (40%--50%) have a mutation in the protein tyrosine phosphatase non-receptor type 11 (*PTPN11*) gene that encodes the protein tyrosine phosphatase, Src homology region 2-domain phosphatase-2 (SHP-2) \[[@b1-kjp-2019-00220]\]. This *PTPN11* mutation results in a gain of function of SHP-2, which acts on the growth hormone (GH) receptor signaling pathway as a negative regulator. *SOS1* mutations, the second most common cause of NS, are observed in approximately 10%--20% of cases \[[@b6-kjp-2019-00220]\]. *RAF1* and *RIT1* mutations have a similar prevalence (8%) \[[@b7-kjp-2019-00220]\]. *PTPN11, SOS1, RAF1*, and *RIT1* comprise 93% of reported mutations \[[@b7-kjp-2019-00220]\].

The causes of growth disturbances in NS were reported as many different mechanisms, including GH deficiency, GH insensitivity, and neurosecretory dysfunction \[[@b1-kjp-2019-00220],[@b8-kjp-2019-00220]\]. GH treatment efficacy is under debate \[[@b9-kjp-2019-00220]\]. It is difficult to systematically compare published data about GH treatment in NS due to heterogeneous protocols, some bias, insufficient numbers of subjects, different cohort selection, and short-term therapy \[[@b10-kjp-2019-00220],[@b11-kjp-2019-00220]\].

Several studies have compared GH treatment efficacy between *PTPN11* mutation-positive and mutation-negative patients \[[@b8-kjp-2019-00220]\]. A number of studies reported that the height standard deviation scores of patients without a *PTPN11* mutation were significantly increased compared to those with *PTPN11* mutations after 1, 2, and 3 years of GH therapy \[[@b8-kjp-2019-00220]\]. NS patients with *PTPN11* mutations may have lower insulin-like growth factor-1 levels and higher serum GH levels, suggestive of mild GH resistance compared to patients without a *PTPN11* mutation \[[@b8-kjp-2019-00220]\].

It is important that GH therapy is started at a younger age, namely before the onset of delayed puberty. It is also believed that a prepubertal start of GH therapy could compensate for the lack of a pubertal growth spurt \[[@b5-kjp-2019-00220]\]. Most researchers asserted that prepubertal status and early initiation of therapy are essential predictors in GH response \[[@b4-kjp-2019-00220]\], however, few studies have reported. Binder \[[@b11-kjp-2019-00220]\] demonstrated a trend toward a higher first-year growth rate in prepubertal NS children without the *PTPN11* mutation. In this regard, the study of Jo et al. \[[@b12-kjp-2019-00220]\] is considered valuable because it compared early GH effects in prepuberty between patients with and those without NS-causing gene mutations. The association between shortterm growth response and genotype seems unsuitable for an analysis of GH effect in NS \[[@b8-kjp-2019-00220],[@b13-kjp-2019-00220]\]. Noordam et al. \[[@b13-kjp-2019-00220]\] reported that the response to GH treatment for 3.0--10.3 years was not significantly different in children with *PTPN11* mutations, compared those without *PTPN11* mutations. There are few reports of final height data in GH-treated NS children. Therefore, there is a lack of evidence that NS patients with the *PTPN11* mutations have a shorter final adult height.

Another important point is the genetic heterogeneity of the study subjects causes variability in the response to GH therapy. Heterozygous mutations in more than 17 genes are known to underlie NS or NS-related disorders. In the study of Jo et al. \[[@b12-kjp-2019-00220]\], the response to GH therapy of NS children in *PTPN11, RAF1*, and *SOS1* mutation groups were compared to those of NS patients in 5 genes (*PTPN11, RAF1, SOS1, KRAS*, and *BRAF*) undetected (FGU) group. There are several problems with organizing patients with NS without mutations in 5 genes into the FUG group, as patients in the FGU group may have other undetected NS-causing genes. In other words, because the FGU group may include multiple genetic characteristics, its use as a control group is not suitable. Moreover, affected signaling proteins of the RAS-MAPK pathway other than the cytosolic protein tyrosine phosphatase encoded by *PTPN11* are not completely understood to be directly implicated in the GH signaling pathway. The GH response of patients with NS-causing gene mutations other than PTPN11 has yet to be clarified \[[@b10-kjp-2019-00220],[@b11-kjp-2019-00220]\]. For these reasons, bias may be unavoidable in the analysis of the GH response in the FGU group. Thus, GH responses in very few patients with each gene mutation may not enable a thorough analysis.

The variety of phenotypes in NS represents different genes with diverse mutations. An increased understanding of the causes of short stature in NS such as RAS-MAPK pathway dysregulation is necessary. In patients with diverse mutations in NS-causing genes, reliable large-scale and case-control studies are crucial in elucidating the long-term effects of GH treatment.
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